271 related articles for article (PubMed ID: 16519882)
1. Molecular advances in medullary thyroid cancer diagnostics.
Hubner RA; Houlston RS
Clin Chim Acta; 2006 Aug; 370(1-2):2-8. PubMed ID: 16519882
[TBL] [Abstract][Full Text] [Related]
2. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
3. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.
Moore SW; Appfelstaedt J; Zaahl MG
J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543
[TBL] [Abstract][Full Text] [Related]
4. RET mutation status in medullary thyroid cancer(MTC) patients and the significance of genetic screening for mutations in their immediate relatives--a preliminary report.
Menon MM; Simha MR
Indian J Pathol Microbiol; 2005 Apr; 48(2):161-5. PubMed ID: 16758654
[TBL] [Abstract][Full Text] [Related]
5. RET genetic screening in patients with medullary thyroid cancer: the Moroccan experience.
Abdelhakim A; Barlier A; Kebbou M; Benabdeljalil N; Timinouni M; Taoufiq F; Roche C; El Antri S
J Cancer Res Ther; 2009; 5(3):198-202. PubMed ID: 19841562
[TBL] [Abstract][Full Text] [Related]
6. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
[TBL] [Abstract][Full Text] [Related]
7. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
Krampitz GW; Norton JA
Cancer; 2014 Jul; 120(13):1920-31. PubMed ID: 24699901
[TBL] [Abstract][Full Text] [Related]
8. [Medullary thyroid carcinoma and some of its particularities].
Sidibé el H
Sante; 2007; 17(1):51-5. PubMed ID: 17897902
[TBL] [Abstract][Full Text] [Related]
9. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene].
Fitze G; Saeger HD; Roesner D; Schackert HK
Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293
[TBL] [Abstract][Full Text] [Related]
10. Management of medullary thyroid carcinoma.
Jiménez C; Hu MI; Gagel RF
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338
[TBL] [Abstract][Full Text] [Related]
11. Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2).
Jimenez C; Gagel RF
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S150-7. PubMed ID: 15135800
[TBL] [Abstract][Full Text] [Related]
12. [Thyroid carcinomas and Hirschsprung's disease--10-year experience with molecular genetic testing of the RET proto-oncogene].
Bendlová B; Dvoráková S; Václavíková E; Sýkorová V; Vlcek P; Skába R
Vnitr Lek; 2006 Oct; 52(10):926-34. PubMed ID: 17063805
[TBL] [Abstract][Full Text] [Related]
13. RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds.
Fialkowski EA; DeBenedetti MK; Moley JF; Bachrach B
J Pediatr Surg; 2008 Jan; 43(1):188-90. PubMed ID: 18206480
[TBL] [Abstract][Full Text] [Related]
14. Management of patients with hereditary medullary thyroid carcinoma.
Fitze G
Eur J Pediatr Surg; 2004 Dec; 14(6):375-83. PubMed ID: 15630638
[TBL] [Abstract][Full Text] [Related]
15. [C634R mutation of the protooncongene RET and molecular diagnosis in multiple endocrine neoplasia type 2 in a large Moroccan family].
Benazzouz B; Hafidi A; Benkhira S; Chraibi A; Kadiri A; Hilal L
Bull Cancer; 2008 Apr; 95(4):457-63. PubMed ID: 18495576
[TBL] [Abstract][Full Text] [Related]
16. Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside.
Machens A; Dralle H
Mol Cell Endocrinol; 2006 Mar; 247(1-2):34-40. PubMed ID: 16343738
[TBL] [Abstract][Full Text] [Related]
17. Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation.
Milos IN; Frank-Raue K; Wohllk N; Maia AL; Pusiol E; Patocs A; Robledo M; Biarnes J; Barontini M; Links TP; de Groot JW; Dvorakova S; Peczkowska M; Rybicki LA; Sullivan M; Raue F; Zosin I; Eng C; Neumann HP
Endocr Relat Cancer; 2008 Dec; 15(4):1035-41. PubMed ID: 18794325
[TBL] [Abstract][Full Text] [Related]
18. Multiple endocrine neoplasia type 2.
Marini F; Falchetti A; Del Monte F; Carbonell Sala S; Tognarini I; Luzi E; Brandi ML
Orphanet J Rare Dis; 2006 Nov; 1():45. PubMed ID: 17105651
[TBL] [Abstract][Full Text] [Related]
19. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.
Learoyd DL; Gosnell J; Elston MS; Saurine TJ; Richardson AL; Delbridge LW; Aglen JV; Robinson BG
Clin Endocrinol (Oxf); 2005 Dec; 63(6):636-41. PubMed ID: 16343097
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the RET proto-oncogene in medullary thyroid carcinoma.
Höppner W
Clin Lab; 2007; 53(5-6):283-4. PubMed ID: 17605402
[No Abstract] [Full Text] [Related]
[Next] [New Search]
